PMID- 10564584
OWN - NLM
STAT- MEDLINE
DCOM- 20000207
LR  - 20131121
IS  - 1045-2257 (Print)
IS  - 1045-2257 (Linking)
VI  - 27
IP  - 1
DP  - 2000 Jan
TI  - Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic 
      leukemia.
PG  - 35-43
AB  - In the present article, two new types of PML/RARA junctions are described. Both 
      were identified in diagnostic samples from two t(15;17)(q22;q21)-positive acute 
      promyelocytic leukemia (APL) patients who failed to achieve complete remission. 
      By using different sets of primers, reverse transcriptase polymerase chain 
      reaction (RT-PCR) of PML/RARA junctions showed atypical larger bands compared 
      with those generated from the three classical PML breakpoints already described. 
      Sequence analysis of the fusion region of the amplified cDNAs allowed us to 
      determine the specificity of these fragments in both patients. This analysis 
      showed two new hybrid transcripts that were 53 and 306 base pairs (bp) longer 
      than that expressed by the NB4 cell line (PML breakpoint within intron 6), and 
      are the result of the direct joining of RARA exon 3 with PML exon 7a (patient 2) 
      or the 5' portion of PML exon 7b (patient 1), respectively. In patient 1, RT-PCR 
      analysis of the reciprocal RARA/PML junction showed a smaller transcript than 
      that expected in bcr1 cases, while in patient 2 no amplified fragment was 
      obtained. Cytogenetic analysis and/or fluorescence in situ hybridization (FISH) 
      showed that both patients had the t(15;17) translocation. The clinical and 
      hematological profiles expressed by the two patients carrying these unexpected 
      types of PML/RARA rearrangement did not differ significantly from that commonly 
      seen in other APLs with the exception of the poor outcome. Genes Chromosomes 
      Cancer 27:35-43, 2000.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Chillon, M C
AU  - Chillon MC
AD  - Hematology Service, Hospital Universitario de Salamanca and Centro de 
      Investigacion del Cancer (CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
FAU - Gonzalez, M
AU  - Gonzalez M
FAU - Garcia-Sanz, R
AU  - Garcia-Sanz R
FAU - Balanzategui, A
AU  - Balanzategui A
FAU - Gonzalez, D
AU  - Gonzalez D
FAU - Lopez-Perez, R
AU  - Lopez-Perez R
FAU - Mateos, M V
AU  - Mateos MV
FAU - Alaejos, I
AU  - Alaejos I
FAU - Rayon, C
AU  - Rayon C
FAU - Arbeteta, J
AU  - Arbeteta J
FAU - Hernandez, J M
AU  - Hernandez JM
FAU - Orfao, A
AU  - Orfao A
FAU - San Miguel, J
AU  - San Miguel J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 04079A1RDZ (Cytarabine)
RN  - 5688UTC01R (Tretinoin)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Base Sequence
MH  - Chromosomes, Human, Pair 15/*genetics
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Cytarabine/administration & dosage
MH  - Exons/genetics
MH  - Fatal Outcome
MH  - Humans
MH  - Idarubicin/administration & dosage
MH  - Leukemia, Promyelocytic, Acute/drug therapy/*genetics
MH  - Male
MH  - Molecular Sequence Data
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Translocation, Genetic/*genetics
MH  - Tretinoin/administration & dosage
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.1002/(SICI)1098-2264(200001)27:1<35::AID-GCC5>3.0.CO;2-W [pii]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2000 Jan;27(1):35-43.